Tenon Medical, Inc.

For the period ended Dec 31, 2025. Filed Mar 27, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 27, 2026

TNON$1.74-0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Convertible Preferred Stock and Stockholders’ Equity

(In thousands, except share data)

Series A Convertible Preferred Stock · Series B Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumula- · Accumula-ted Other Compre-
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	ted Deficit	hensive Loss	Total
Balance at December 31, 2023	—	$—	—	$—	325,039	$—	$55,897	$(55,073)	$(46)	$778
Stock-based compensation expense	—	—	—	—	—	—	3,845			3,845
Release of restricted stock units	—	—	—	—	9,926	—	—			—
Issuance of Series A preferred stock and warrants, net of issuance costs	256,968	3,300	—	—	—	—	254	—	—	3,554
Issuance of Series B preferred stock and warrants, net of issuance costs	—	—	86,454	452	—	—	37	—	—	489
Issuance of common stock, prefunded warrants, and warrants, net of issuance costs	—	—	—	—	55,000	—	3,846	—	—	3,846
Issuance of common stock upon exercise of prefunded warrants	—	—	—	—	1,167,850	1	(1)	—	—	—
Issuance of common stock and warrants under inducement agreement, net of issuance costs	—	—	—	—	1,222,850	1	4,305	—	—	4,306
Issuance of common stock upon exercise of warrants	—	—	—	—	32,266	—	812	—	—	812
Issuance of common stock, net of issuance costs	—	—	—	—	178,048	—	1,968	—	—	1,968
Issuance of common stock for reverse stock split	—	—	—	—	147,825	1	(1)	—	—	—
Other comprehensive income	—	—	—	—	—	—	—	—	46	46
Net loss	—	—	—	—	—	—	—	(13,673)		(13,673)
Balance at December 31, 2024	256,968	3,300	86,454	452	3,138,804	3	70,962	(68,746)	—	5,971
Stock-based compensation expense	—	—	—	—	—	—	1,691	—	—	1,691
Issuance of common stock, pre-funded warrants and warrants under inducement agreement, net of issuance costs	—	—	—	—	2,445,700	3	2,732	—	—	2,735
Issuance of common stock, prefunded warrants, and warrants, net of issuance costs	—	—	—	—	2,005,000	2	3,522	—	—	3,524
Shares issued for acquisition of assets of SiVantage, Inc.	—	—	—	—	710,300	1	1,365	—	—	1,366
Issuance of common stock upon conversion of Series A convertible preferred stock	(52,809)	(678)	—	—	300,005	—	678	—	—	—
Issuance of common stock and warrants, net of issuance costs	—	—	—	—	2,217,904	2	2,728	—	—	2,730
Release of restricted stock units	—	—	—	—	33,560	—	—	—	—	—
Deferred financing costs	—	—	—	—	—	—	(421)	—	—	(421)
Net loss	—	—	—	—	—	—	—	(12,556)	—	(12,556)
Balance at December 31, 2025	204,159	$2,622	86,454	$452	10,851,273	$11	$83,257	$(81,302)	$—	$5,040

See Reports of Independent Registered Public Accounting Firms.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.